The compound according to Formula Ic or a pharmaceutically acceptable salt thereof, wherein: R is H or fluoro, Y 3 is CH or N, X B is selected from F, Cl, -OCH 3, -CF 3 and-OCF 3, X is selected from: H, -OH, -NH 2 and -N -C -OC 1-4 alkyl. U 1 is selected from: 1-methylethyl, tetrahydro-2H-pyran-4-yl, wherein W 1 is CH or N, and X c is selected from F, Cl, -OCH 3, -CF 3 and-OCF 3; Z A is selected from the group consisting of: hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, ArylA, HetA and HetB, wherein said C 1-10 alkyl, C 2-10 alkenyl and C 3-7 cycloalky are optionally substituted with 1 to 6 substituents as allowed by valence independently selected from the group consisting of: fluoro, hydroxy, carbamoyl, C 3-6 cycloalkyl, C O-C 1-6 alkyl, C OH, C -C 1-6 alkyl, N -C 1-6 alkyl, N(-C 1-6 alkyl) 2, ArylA, ArylA-O-, HetA, HetA-O-, HetB and HetB-O-; each ArylA is an aryl which is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 4 Y B; each HetA is a heteroaromatic ring system which is independently (i) a 5- or 6-membered monocyclic heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) is a 9-, 10- or 11-membered bicyclic heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the monocylcic ring (i) or the bicyclic ring (ii) is optionally substituted with from 1 to 4 YC; and each HetB is independently a 4- to 7-membered monocyclic, or 9-, 10- or 11-membered bicyclic, saturated or unsaturated, non-aromatic heterocyclic ring system containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S or S 2, and wherein the saturated or unsaturated heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, CN, C 1-6 alkyl, OH, oxo, O-C 1-6 alkyl, C 1-6 haloalkyl, O-C 1-6 haloalkyl, C NH 2, C N -C 1-6 alkyl, C N(-C 1-6 alkyl) 2, C H, C -C 1-6 alkyl, CO 2 H, CO 2 -C 1-6 alkyl, N SO 2 -C 1-6 alkyl, N C -C 1-6 alkyl, SO 2 H, SO 2 -C 1-6 alkyl, C N -C 1-6 haloalkyl, C N(-C 1-6 alkyl)(-C 1-6 haloalkyl), C N(-C 1-6 haloalkyl) 2, C -C 1-6 haloalkyl, CO 2 -C 1-6 haloalkyl, N SO 2 -C 1-6 haloalkyl, N C -C 1-6 haloalkyl, or SO 2 -C 1-6 haloalkyl and m and n are independently 0, 1 or 2. R is H or fluoro, Y 3 is CH or N, X B is selected from F, Cl, -OCH 3, -CF 3 and-OCF 3, X is selected from: H, -OH, -NH 2 and -N -C -OC 1-4 alkyl. U 1 is selected from: 1-methylethyl, tetrahydro-2H-pyran-4-yl, wherein W 1 is CH or N, and X c is selected from F, Cl, -OCH 3, -CF 3 and-OCF 3; Z A is selected from the group consisting of: hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, ArylA, HetA and HetB, wherein said C 1-10 alkyl, C 2-10 alkenyl and C 3-7 cycloalky are optionally substituted with 1 to 6 substituents as allowed by valence independently selected from the group consisting of: fluoro, hydroxy, carbamoyl, C 3-6 cycloalkyl, C O-C 1-6 alkyl, C OH, C -C 1-6 alkyl, N -C 1-6 alkyl, N(-C 1-6 alkyl) 2, ArylA, ArylA-O-, HetA, HetA-O-, HetB and HetB-O-; hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, ArylA, HetA and HetB, each ArylA is an aryl which is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 4 Y B; each HetA is a heteroaromatic ring system which is independently (i) a 5- or 6-membered monocyclic heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) is a 9-, 10- or 11-membered bicyclic heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the monocylcic ring (i) or the bicyclic ring (ii) is optionally substituted with from 1 to 4 YC; and each HetB is independently a 4- to 7-membered monocyclic, or 9-, 10- or 11-membered bicyclic, saturated or unsaturated, non-aromatic heterocyclic ring system containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, where each S is optionally oxidized to S or S 2, and wherein the saturated or unsaturated heterocyclic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, CN, C 1-6 alkyl, OH, oxo, O-C 1-6 alkyl, C 1-6 haloalkyl, O-C 1-6 haloalkyl, C NH 2, C N -C 1-6 alkyl, C N(-C 1-6 alkyl) 2, C H, C -C 1-6 alkyl, CO 2 H, CO 2 -C 1-6 alkyl, N SO 2 -C 1-6 alkyl, N C -C 1-6 alkyl, SO 2 H, SO 2 -C 1-6 alkyl, C N -C 1-6 haloalkyl, C N(-C 1-6 alkyl)(-C 1-6 haloalkyl), C N(-C 1-6 haloalkyl) 2, C -C 1-6 haloalkyl, CO 2 -C 1-6 haloalkyl, N SO 2 -C 1-6 haloalkyl, N C -C 1-6 haloalkyl, or SO 2 -C 1-6 haloalkyl and m and n are independently 0, 1 or 2.